These data demonstrate that reduced steatosis is independent of altered β-cell function and glycemic control and likely that IL-22RA1-hepatic signaling is required for IL-22-ScFv-driven improvements in the liver (Fig. 5b–e). The gene discussed is IL22RA1; the disease is steatosis.